Preclinical Evaluation of Linear HPMA-Doxorubicin Conjugates with pH-Sensitive Drug Release: Efficacy, Safety, and Immunomodulating Activity in Murine Model
In vivo efficacy and safety of HPMA-based copolymers armed with doxorubicin via a spacer containing pH-sensitive linkage that can be prepared within a broad range of attached drug contents (1) was tested in murine tumor models.
Mice bearing T cell lymphoma EL4 or B cell lymphoma 38C13 were treated with a single dose of the conjugate (15, 25, and 75 mg Dox eq./kg i.v.) in a therapeutic regime. Anti-tumor resistance of the cured animals was proved by a second challenge with a lethal dose of tumor cells without additional treatment.
The content of drug bound to the polymer is an important parameter in relation to the conjugate therapeutic efficacy. The best anti-tumor effects were produced by conjugates with 10 – 13 wt% of bound doxorubicin. Free doxorubicin up to 4.6% relative to total drug content had no impact on the treatment efficacy and acute toxicity. The conjugates induced a complete cure of mice and regular treatment-dependent development of specific anti-tumor resistance. No myelosuppression or organ damage was observed.
A well-defined HPMA copolymer-doxorubicin conjugate with pH-sensitive drug release is a good candidate for clinical trials as it has remarkable anti-tumor efficacy and a favorable safety profile.
KEY WORDSdoxorubicin immunomodulation murine lymphoma N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate tumor resistance
high mobility group box-1
phosphate buffered saline
The work was supported by grant KAN 200200651, Premium Academiae, and Institutional Research Concept AV0Z50200510. Authors appreciate the funding support from pharmaceutical company Zentiva, k.s. (Czech Republic), and thank Mrs. Helena Mišurcová and Ms. Pavlína Jungrová for excellent technical assistance.
- 1.Etrych T, Mrkvan T, Chytil P, Konak C, Rihova B, Ulbrich K. N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation. J Appl Polym Sci. 2008;109:3050–61.CrossRefGoogle Scholar
- 9.Duncan R, Cable HC, Lloyd JB, Rejmanova P, Kopecek J. Polymers containing enzymatically degradable bonds 7. Design of oligopeptide side chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol Chem. 1984;184:1997–2008.CrossRefGoogle Scholar
- 15.Kovar L, Strohalm J, Chytil P, Mrkvan T, Kovar M, Hovorka O, et al. The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line. Bioconjug Chem. 2007;18:894–902.CrossRefPubMedGoogle Scholar
- 16.Hovorka O, Etrych T, Subr V, Strohalm J, Ulbrich K, Rihova B. HPMA based macromolecular therapeutics: internalization, intracellular pathway and cell death depend on the character of covalent bond between the drug and the peptidic spacer and also on spacer composition. J Drug Target. 2006;14:391–403.CrossRefPubMedGoogle Scholar
- 25.Choi W-M, Kopeckova P, Minko T, Kopecek J. Synthesis of HPMA copolymer containing adriamycin bound via an acid-labile spacer and its activity toward human ovarian carcinoma cells. J Bioact Comp Polym. 1999;14:447–56.Google Scholar
- 30.Seymour LW, Duncan R, Strohalm J, Kopecek J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res. 1987;21:1341–58.CrossRefPubMedGoogle Scholar
- 34.Rihova B, Kopeckova P, Strohalm J, Rossmann P, Vetvicka V, Kopecek J. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin Immunol Immunopathol. 1988;46:100–14.CrossRefPubMedGoogle Scholar
- 35.Rihova B, Bilej M, Vetvicka V, Ulbrich K, Strohalm J, Kopecek J, et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials. 1989;10:335–42.CrossRefPubMedGoogle Scholar
- 42.Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates Cancer Research Campaign Phase I/II Committee. Clin Cancer Res. 1999;5:83–94.PubMedGoogle Scholar